Market Indices
Sector Heatmap
KOD — Kodiak Sciences Inc Common Stock
NasdaqKodiak Sciences Inc Common Stock
- O
- 92.86
- H
- 96.64
- L
- 87.58
- V
- 3.17M
KOD — Latest News & Headlines
20 StoriesKodiak Sciences (KOD) Stock Looks Overvalued After Its 15x Run - Yahoo Finance
Kodiak Sciences (KOD) Stock Looks Overvalued After Its 15x Run Yahoo Finance
Why This Regeneron Eye Rival Just Catapulted More Than 170% - Investor's Business Daily
Why This Regeneron Eye Rival Just Catapulted More Than 170% Investor's Business Daily
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - TradingView
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears TradingView
Kodiak Sciences (Nasdaq:KOD) - Stock Analysis - Simply Wall Street
Kodiak Sciences (Nasdaq:KOD) - Stock Analysis Simply Wall Street
Results are due Monday from a study of two potential treatments for an age-related eye disease. - Stock Titan
Results are due Monday from a study of two potential treatments for an age-related eye disease. Stock Titan
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - Stocktwits
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? Stocktwits
Stocks making the biggest moves midday: MongoDB, Boeing, Kodiak Sciences, Roblox, Nvidia & more - CNBC
Stocks making the biggest moves midday: MongoDB, Boeing, Kodiak Sciences, Roblox, Nvidia & more CNBC
KOD Stock Jumps As Traders Position For Phase 3 Data Wave - StocksToTrade
KOD Stock Jumps As Traders Position For Phase 3 Data Wave StocksToTrade
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - Yahoo Finance
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears Yahoo Finance
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ - TradingView
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ TradingView
Kodiak Sciences (KOD) Stock Trades At A Huge Premium On Phase 3 Results - Simply Wall Street
Kodiak Sciences (KOD) Stock Trades At A Huge Premium On Phase 3 Results Simply Wall Street
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ - Stocktwits
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ Stocktwits
KOD Stock Jumps As Phase 3 Catalysts Draw Wall Street Targets - StocksToTrade
KOD Stock Jumps As Phase 3 Catalysts Draw Wall Street Targets StocksToTrade
In a vision trial, 54% of patients went six months between eye treatments - Stock Titan
In a vision trial, 54% of patients went six months between eye treatments Stock Titan
Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial - Yahoo Finance
Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial Yahoo Finance
KOD Stock Jumps As Phase 3 Catalysts And Analyst Targets Align - StocksToTrade
KOD Stock Jumps As Phase 3 Catalysts And Analyst Targets Align StocksToTrade
This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today - Yahoo Finance
This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today Yahoo Finance
This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today - TradingView
This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today TradingView
Options at $2.49 a share are among those Kodiak Sciences (KOD) CEO exercised. - Stock Titan
Options at $2.49 a share are among those Kodiak Sciences (KOD) CEO exercised. Stock Titan
Kodal Minerals PLC (KOD.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
Kodal Minerals PLC (KOD.L) Stock Price, News, Quote & History Yahoo! Finance Canada